Analyst Price Targets — EVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 9:58 am | Swayampakula Ramakanth | H.C. Wainwright | $4.00 | $2.14 | TheFly | Evotec price target lowered to $4 from $7 at H.C. Wainwright |
| July 15, 2026 6:51 am | — | Macquarie | $2.00 | $2.14 | StreetInsider | TD Cowen Downgrades Evotec (EVO) to Hold |
| August 14, 2025 10:04 am | Douglas Tsao | H.C. Wainwright | $7.00 | $3.81 | TheFly | Evotec price target lowered to $7 from $8 at H.C. Wainwright |
| August 15, 2024 6:39 am | Douglas Tsao | H.C. Wainwright | $8.00 | $3.22 | StreetInsider | Evotec (EVO) PT Lowered to $8 at H.C. Wainwright |
| April 25, 2024 6:39 am | Douglas Tsao | H.C. Wainwright | $11.00 | $5.23 | StreetInsider | Evotec (EVO) PT Lowered to $11 at H.C. Wainwright |
| December 9, 2022 6:39 am | — | H.C. Wainwright | $12.00 | $8.38 | Benzinga | HC Wainwright & Co. Initiates Coverage On Evotec with Buy Rating, Announces Price Target of $12 |
Latest News for EVO
Evotec SE (EVO) Q2 2026 Earnings Call Transcript
Evotec NASDAQ: EVO reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements.
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook PR Newswire
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook.
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EVO.
U.S. House Trading
No House trades found for EVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.